Mesothelioma Clinical Trials for 2010
Past Clinical Trials:
2009 Clinical Trials
The following clinical trials for mesothelioma are seeking participants as of January 2010. The studies are sorted by their relevance to malignant mesothelioma. For more information on these or other clinical trials in progress, go to ClinicalTrials.gov.
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin / NF2 Loss as a Biomarker to Predict Sensitivity
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: everolimus
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma
Interventions: Drug: Pemetrexed; Drug: Cisplatin
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
Conditions: Malignant Mesothelioma; Metastatic Cancer
Interventions: Other: talc; Procedure: therapeutic thoracoscopic surgery; Procedure: therapeutic
thoracoscopy; Procedure: therapeutic videothoracoscopy
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Interventions: Biological: SS1(dsFv)-PE38 immunotoxin; Drug: cisplatin; Drug: pemetrexed disodium;
Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: pharmacological study; Procedure: quality-of-life assessment
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Condition: Mesothelioma
Interventions: Drug: MORAb-009; Drug: Premetrexed; Drug: Cisplatin
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Procedure: Extrapleural pneumonectomy (EPP), Pleurectomy/Decortication; Drug: cisplatin; Drug: gemcitabine; Drug: amifostine; Drug: sodium thiosulfate
Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
Conditions: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
Conditions: Lung Cancer; Mesothelioma
Intervention:
Tomotherapy Treatment for Mesothelioma
Condition: Mesothelioma
Intervention: Procedure: Tomotherapy
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: bortezomib; Procedure: quality-of-life assessment
AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: bortezomib; Drug: cisplatin
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Other: laboratory biomarker analysis;
Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy;
Procedure: quality-of-life assessment; Radiation: radiation therapy
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Conditions: Malignant Mesothelioma; Pulmonary Complications
Interventions: Genetic: microarray analysis; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Interventions: Dietary Supplement: vitamin B12; Drug: cisplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
Conditions: Malignant Mesothelioma; Metastatic Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: study of high risk factors
Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases From Cancers of Non-Thoracic Origin
Conditions: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: gene expression analysis; Procedure: bronchoscopy; Procedure: endoscopic biopsy; Procedure: needle biopsy
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: bevacizumab; Drug: cisplatin; Drug: pemetrexed
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Milataxel
Dasatinib in Resectable Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Dasatinib
Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma; Lung Cancer
Interventions: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin and Intensity Modulated Radiation Therapy
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Bevacizumab, Pemetrexed, Carboplatin
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Condition: Pleural Mesothelioma
Interventions: Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic);
Drug: Cisplatin and doxorubicin (intrapleural)
Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases
Conditions: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Interventions: Drug: celecoxib; Drug: decitabine; Drug: romidepsin
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Condition: Mesothelioma
Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin; Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Conditions: Pleural Mesothelioma; Malignant Pleural Mesothelioma
Interventions: Drug: Cisplatin; Drug: Sodium Thiosulfate; Drug: ALIMTA
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
Short Neoadjuvant Hemithoracic IMRT for MPM
Condition: Malignant Pleural Mesothelioma
Intervention: Other: Pre-op RT +/- chemotherapy
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Mesothelioma
Interventions: Drug: N-Acetylcysteine; Drug: Placebo
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant
Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
Conditions: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Interventions: Drug: alvocidib; Drug: romidepsin
Optical Coherence Tomography of the Airway in Detecting Abnormal Cells in Patients Undergoing Surgery for Lung Cancer or Lung Disease
Conditions: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Precancerous/Nonmalignant Condition
Interventions: Procedure: bronchoscopic and lung imaging studies; Procedure: diagnostic bronchoscopy; Procedure: histopathologic examination; Procedure: optical coherence tomography
Gene Therapy for Pleural Malignancies
Conditions: Pleural Mesothelioma; Metastatic Pleural Effusions
Intervention: Gene Transfer: BG00001 (adenoviral-mediated interferon-beta)
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Conditions: Mesothelioma; Non-small Cell Lung Cancer; Neoplasms
Intervention: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
Conditions: Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Mesothelioma
Interventions: Procedure: cytoreductive surgery; Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
